Mirum Pharmaceuticals MIRM

$ 40.47 0.05%

Quarterly report 2024-Q2
added 08-07-2024

Mirum Pharmaceuticals Balance Sheet 2011-2024 | MIRM

Annual Balance Sheet Mirum Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-285 M	-25.8 M	-28.7 M	-137 M	-8.32 M	-52 M	-	-	-	-	-	-	-
Long Term Debt	617 K	1.26 M	1.9 M	2.63 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1.1 M	931 K	711 K	636 K	397 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	50.3 M	3.29 M	59.8 M	-	-	-	-	-	-	-
Total Current Liabilities	87.1 M	64.7 M	42.6 M	18.5 M	13.1 M	-	-	-	-	-	-	-	-
Total Liabilities	398 M	211 M	174 M	68.8 M	16.4 M	62.3 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-556 M	-393 M	-257 M	-173 M	-69.9 M	-17.3 M	-	-	-	-	-	-	-
Total Assets	647 M	353 M	295 M	241 M	147 M	52 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	286 M	28 M	31.3 M	142 M	12 M	-	-	-	-	-	-	-	-
Book Value	249 M	142 M	120 M	172 M	130 M	-10.3 M	-	-	-	-	-	-	-
Total Shareholders Equity	249 M	142 M	120 M	172 M	130 M	-17.3 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Mirum Pharmaceuticals

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	8.24 M	328 K	617 K	868 K	1.15 M	1.06 M	1.26 M	1.31 M	-	1.71 M	1.9 M	2.09 M	2.27 M	2.45 M	2.63 M	2.63 M	2.63 M	2.63 M	3.25 M	3.25 M	3.25 M	3.25 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	432 M	417 M	398 M	382 M	365 M	192 M	211 M	195 M	-	169 M	174 M	179 M	152 M	88.4 M	68.8 M	68.8 M	68.8 M	68.8 M	16.4 M	16.4 M	16.4 M	16.4 M	2.45 M	2.45 M	2.45 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-606 M	-582 M	-556 M	-521 M	-497 M	-423 M	-393 M	-356 M	-	-294 M	-257 M	-315 M	-268 M	-224 M	-173 M	-173 M	-173 M	-173 M	-69.9 M	-69.9 M	-69.9 M	-69.9 M	-17.3 M	-17.3 M	-17.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	661 M	652 M	647 M	651 M	444 M	334 M	353 M	364 M	-	278 M	295 M	235 M	248 M	222 M	241 M	241 M	241 M	241 M	147 M	147 M	147 M	147 M	52 M	52 M	52 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	233 M	303 M	286 M	303 M	297 M	49.4 M	28 M	35.8 M	-	46.3 M	31.3 M	55.8 M	91.9 M	90.7 M	142 M	142 M	142 M	142 M	12 M	12 M	12 M	12 M	52 M	52 M	52 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	229 M	235 M	249 M	269 M	78.6 M	141 M	142 M	169 M	-	109 M	120 M	56.4 M	95.7 M	134 M	172 M	172 M	172 M	172 M	130 M	130 M	130 M	130 M	49.5 M	49.5 M	49.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	229 M	235 M	249 M	269 M	78.6 M	141 M	142 M	169 M	111 M	109 M	120 M	56.4 M	95.7 M	134 M	172 M	172 M	172 M	172 M	130 M	130 M	130 M	130 M	-17.3 M	-17.3 M	-17.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency